Results 201 to 210 of about 361,445 (287)

Transmembrane MUC1 assists oral microbial colonization in oral mucosa of potentially malignant disorders and oral squamous carcinoma

open access: yesEuropean Journal of Oral Sciences, EarlyView.
Abstract Transmembrane mucin 1 (tMUC1) provides oral mucosal barrier against pathogens. The invasion of oncopathogenic microbes can promote cancerous proliferation of cells via inflammatory responses, abnormal cellular signaling, angiogenesis, anti‐adhesion, and tumorigenesis.
Lauriina Soiniemi   +4 more
wiley   +1 more source

Cannabis Use and Benign Salivary Gland Neoplasms.

open access: yesJAMA Otolaryngol Head Neck Surg
Gallagher TJ   +4 more
europepmc   +1 more source

A guide to host genetic determinants of female microbiome composition across distinct anatomical niches

open access: yesThe FEBS Journal, EarlyView.
Host genetic variation in immune regulation and cell signalling genes was associated with microbiome composition across vaginal, gut, oral and skin sites, while associations involving metabolic function, epithelial barrier integrity and hormonal processes were more site‐specific. Overall, our findings indicate that host genetic variation contributes to
Isabella Margaret Davidson   +4 more
wiley   +1 more source

Clear cell changes in salivary gland neoplasms: A 20-year retrospective study. [PDF]

open access: yesMed Oral Patol Oral Cir Bucal, 2017
Woods T   +4 more
europepmc   +1 more source

Prevalence of Oral Mucosal Lesions in Finnish Adults—Findings From the Healthy Finland Survey

open access: yesGerodontology, EarlyView.
ABSTRACT Objectives Oral mucosal lesions (OMLs) are abnormal findings of the oral mucosa. OMLs can be a localized disease due to trauma or infections, a manifestation of systemic or dermatological disease, or a sign of neoplasia. The aim of this study was to assess the prevalence of OMLs among Finnish adults.
Mirjami J. Rintala   +5 more
wiley   +1 more source

Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing. [PDF]

open access: yesDis Model Mech, 2018
Alamri AM   +10 more
europepmc   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach   +2 more
wiley   +1 more source

Italian Patients Journey for Gene Therapy in Haemophilia A

open access: yesHaemophilia, EarlyView.
ABSTRACT Introduction Gene therapy (GT) provides sustained FVIII levels without repeated infusions in Hemophilia A (HA) patients thus overcoming a major limitation of replacement therapy. However, issues remain e.g., patient selection criteria, duration and variability of transgene expression, quality of life and long‐term safety.
Giovanni Di Minno   +19 more
wiley   +1 more source

Home - About - Disclaimer - Privacy